Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland
•NXP900 is a SRC/YES1 Kinase Inhibitor with a Novel and Differentiated Mechanism of Action.FORT LEE, NJ , Sept. 14, 2021...